ACCESS Newswire
04 Aug 2022, 15:31 GMT+10
New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets
VANCOUVER, BC / ACCESSWIRE / August 4, 2022 / RepliCel Life Sciences Inc. (OTCPK:REPCF)(TSXV:RP)(FRA:P6P2) ('RepliCel' or the 'Company'), a company developing novel, next-generation injection technologies as well as cell-based regenerative medicine products in aesthetics and orthopedics, is pleased to announce the granting of several patents covering novel aspects of the DermaPrecise™ product portfolio, as well as the granting and/or allowance of four other patent applications for its skin rejuvenation and tendon regeneration technologies.
RepliCel has now been granted patents for DermaPrecise™ by the patent offices in the Unites States (Patent No. 11,311,684) and Japan (Patent No. 6718472B2), both of which are key, near-term markets for RepliCel's cell therapies and the DermaPrecise™ product line. RepliCel has also received a notice of allowance in New Zealand for a corresponding patent application.
'RepliCel has a growing number of allowed and granted patents globally with respect to its innovative DermaPrecise™ injector, control unit and consumables,' stated RepliCel President and CEO, R. Lee Buckler. 'With the positive results we are now seeing in testing of the DermaPrecise™ injection system, we continue to generate patentable innovations which serve to strengthen the clinical and commercial value of this next-generation injection technology.'
Additionally, RepliCel has been granted:
About the DermaPrecise Product Line
The DermaPrecise™ Injector is an electronic injection system designed to offer new levels of control over any injection into the intro-dermal and subcutaneous layers for which precision of depth, dose and/or delivery matters.
About RepliCel's Skin and Tendon Programs
Both RepliCel's cell-based skin rejuvenation product (RCS-01) and its cell-based tendon regeneration product (RCT-01) have been the subject of successful phase 1 clinical studies. RepliCel is currently preparing for next-phased clinical testing and commercialization of two cell-based regenerative medicines in Japan. In China, RepliCel's partner, YOFOTO China Health Company, is currently preparing for phase 2 studies in China of these same therapies in collaboration with RepliCel.
About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the Company believes is approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. These conditions, often associated with aging, are caused by a deficit of healthy cells required for normal tissue healing and function. These cell therapy product candidates are based on RepliCel's innovative technology, utilizing cell populations isolated from a patient's healthy hair follicles.
The Company's cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 has been the subject of successful safety and dose-finding clinical studies and is now the subject of its third clinical study evaluating efficacy for the treatment of male and female hair loss due to androgenetic alopecia. This ongoing study is being funded by Shiseido Company Limited pursuant to a license agreement which has now been terminated but is the subject of an arbitration regarding Shiseido's rights to the product for Asia. RepliCel maintains the undisputed rights to RCH-01 for the rest of the world. RCT-01 and RCS-01 are exclusively licensed in Greater China to YOFOTO (China) Health Company. RepliCel and YOFOTO are currently co-developing these products in China. RepliCel maintains the rights to these products outside of Greater China.
RepliCel has also developed a proprietary injection device (DermaPrecise™) and related consumables, which is expected to improve the administration of its cell therapy products and certain other injectables. YOFOTO has exclusively licensed the commercial rights for the DermaPrecise™ device and consumables in Greater China for dermatology applications and is expected to first launch the product in Hong Kong upon it being approved for market launch in either the United States or Europe. Please visit replicel.com for additional information.
Notable Facts:
For more information, please contact:
Lee Buckler, CEO and President
604-248-8693
[email protected]
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: RepliCel Life Sciences Inc.
Get a daily dose of Tennessee Daily news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Tennessee Daily.
More InformationHONOLULU, Hawaii: Maui's mayor has proposed a plan to reduce vacation rentals to help with the housing shortage caused by the 2023...
WASHINGTON, D.C.: U.S. construction activity gained momentum in February, helped by falling mortgage rates that gave a boost to residential...
SINGAPORE: BOC Aviation is betting big on the future of air travel, placing major orders with both Airbus and Boeing as it moves to...
SAN FRANCISCO, California: A wave of Ghibli-inspired AI artwork has sent ChatGPT usage skyrocketing, as users have embraced the image-generation...
LONDON, U.K.: Virgin Atlantic is seeing signs of cooling demand from U.S. travelers heading to the UK, a shift that comes after a strong...
NEW YORK, New York - The rout in U.,S. and global stock markets continued and even heightened on Friday, as investors around the world...
WASHINGTON, D.C.: Many government workers who help run Head Start, a federally funded preschool program, have been put on leave. The...
LONDON/DETROIT: As U.S. automakers brace for the financial impact of new 25 percent tariffs, car dealers with inventory built before...
WASHINGTON, D.C.: U.S. construction activity gained momentum in February, helped by falling mortgage rates that gave a boost to residential...
WASHINGTON, D.C.: Boeing's top executive faced lawmakers on April 2 as the company worked to repair its reputation following a string...
SINGAPORE: BOC Aviation is betting big on the future of air travel, placing major orders with both Airbus and Boeing as it moves to...
PRESCOTT, Arizona: More than 1,000 firefighters and fire managers recently trained at the annual wildfire academy in Arizona. They...